Preventive strategies used by GI physicians during the COVID-19 pandemic

Hormati, Ahmad; Ghadir, Mohammad Reza; Zamani, Farhad; Khodadadi, Javad; Afifian, Mahboubeh; Ahmadpour, Sajjad

doi:10.1016/j.nmni.2020.100676

Cited by 13 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From February 21 to June 20, 2020, more than 89,000 cases have been diagnosed with COVID-19 in the authors' country of Iran, with 6,150 deaths reported ( Jahangiri, Jahangiri, & Najafgholipour, 2020 ; Nikpouraghdam et al, 2020 ; Shojaee et al, 2020 ). Staying at home or quarantining in an isolated center and minimizing going out are effective ways to battle the spread of COVID-19 ( Aminnejad & Hormati, 2020 ; Hormati, Ghadir, Foroghi Ghomi, et al, 2020 ; Hormati, Ghadir, Zamani, et al, 2020 ; Hormati, Niya, et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…According to the incidence of some GI symptoms in patients with COVID-19 globally, the authors' country is no exception. After the first outbreak of COVID-19 in Qom City, Iran, the number of patients referred to our GI clinics increased by 20% ( Hormati, Ghadir, Zamani, et al, 2020 ; Hormati, Shahhamzeh, Afifian, 2020 ; Hormati, Shahhamzeh, Aminnejad, et al, 2020 ). The incidence of GI complications during COVID-19 is unexpected, and most of these GI symptoms are resistant to medications.…”

Section: Discussionmentioning

confidence: 99%

“…Because performing these procedures requires a close proximity between the endoscopist, the nurse(s), and the infected patient, the possibility of infection in our clinic personnel is increased ( Almadi et al, 2020 ). As a result, we have attentively used recommended infection control approaches to protect the health of our GI team during risky procedures ( Hormati, Ghadir, Zamani, et al, 2020 ; Hormati, Niya, et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Abbasinia

Hormati

Hossaini

et al. 2021

Gastroenterology Nursing

View full text Add to dashboard Cite

After the outbreak of novel coronavirus disease 2019 (COVID-19) in Wuhan, China, its spread to other countries is rapidly increasing. In this integrative review, we report the prevalence of gastrointestinal symptoms in patients with COVID-19. For this purpose, available articles on gastrointestinal manifestations in patients with COVID-19, which were reported from China, were reviewed. All reviewed articles were searched from December 11, 2019, to June 20, 2020, based on specific key words. Related findings in these articles show that the main target of COVID-19 is lung tissue, as after the virus enters the body, it mainly causes respiratory symptoms in affected patients. But in addition to respiratory symptoms, it is possible that, over time, these patients present with other symptoms, the most obvious of which are gastrointestinal symptoms. It is well documented that diarrhea and vomiting are the most common gastrointestinal symptoms in COVID-19 patients. As part of this report, we also look at the incidence and frequency of gastrointestinal symptoms in COVID-19 patients in Iran. The results can be used by providers as a guideline for better management of gastrointestinal symptoms in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Abbasinia

Hormati

Hossaini

et al. 2021

Gastroenterology Nursing

View full text Add to dashboard Cite

show abstract

“…All gastroenterologists who are on call and who routinely worked in referral hospitals are at risk of viral infection, and unusual presentation of COVID-19 may expose them unexpectedly to the disease. 6,7 We surveyed these specialists to evaluate the prevalence of COVID-19 and hospitalization using a standard protocol for COVID-19 diagnosis. We distributed a questionnaire to all gastrointestinal wards in Iran, and we received responses from~480 gastroenterologists by March 26, 2020.…”

mentioning

confidence: 99%

“…Furthermore, patients with gastrointestinal symptoms may represent a source of underdiagnosed COVID-19 cases because they do not present with classic symptoms of the disease such as fever and respiratory signs. 6,7 Personal protection equipment (PPE) is crucial for preventing exposure to the virus. Various protocols have been recommended for PPE for clinicians as well as patients.…”

mentioning

confidence: 99%

COVID-19 in the endoscopy ward: A potential risk for gastroenterologists

Hormati

Niya

Ghadir

et al. 2020

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

COVID‐19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta‐analysis

Lee

Wasuwanich

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

The susceptibility, risk factors, and prognosis of COVID‐19 in patients with inflammatory bowel disease (IBD) remain unknown. Thus, our study aims to assess the prevalence and clinical outcomes of COVID‐19 in IBD. We searched PubMed, EMBASE, and medRxiv from 2019 to 1 June 2022 for cohort and case‐control studies comparing the prevalence and clinical outcomes of COVID‐19 in patients with IBD and in the general population. We also compared the outcomes of patients receiving and not receiving 5‐aminosalicylates (ASA), tumour necrosis factor antagonists, biologics, systemic corticosteroids, or immunomodulators for IBD. Thirty five studies were eligible for our analysis. Pooled odds ratio of COVID‐19‐related hospitalisation, intensive care unit (ICU) admission, or death in IBD compared to in non‐IBD were 0.58 (95% confidence interval (CI) = 0.28–1.18), 1.09 (95% CI = 0.27–4.47), and 0.67 (95% CI = 0.32–1.42), respectively. Inflammatory bowel disease was not associated with increased hospitalisation, ICU admission, or death. Susceptibility to COVID‐19 did not increase with any drugs for IBD. Hospitalisation, ICU admission, and death were more likely with 5‐ASA and corticosteroid use. COVID‐19‐related hospitalisation (Odds Ratio (OR): 0.53; 95% CI = 0.38–0.74) and death (OR: 0.13; 95% CI = 0.13–0.70) were less likely with Crohn's disease than ulcerative colitis (UC). In conclusion, IBD does not increase the mortality and morbidity of COVID‐19. However, physicians should be aware that additional monitoring is needed in UC patients or in patients taking 5‐ASA or systemic corticosteroids.

show abstract

Preventive strategies used by GI physicians during the COVID-19 pandemic

Cited by 13 publications

References 4 publications

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients

COVID-19 in the endoscopy ward: A potential risk for gastroenterologists

COVID‐19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta‐analysis

Contact Info

Product

Resources

About